# ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Source: https://onco.cc/trials/nct05830123/  
OnCo record `nct05830123` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HS-20093 in osteosarcoma, run by Hansoh BioMedical R&D Company, now recruiting.

## Summary

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas is a phase 2 interventional study registered as NCT05830123 by Hansoh BioMedical R&D Company, with 170 participants planned, started 2023-06-08 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20093. Conditions listed: Osteosarcoma, Sarcoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05830123
- Phase: 2
- Setting: ARTEMIS-002: A Phase 2, Multicenter, Open-label Study of Intravenous Administration of HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Sponsor: Hansoh BioMedical R&D Company
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT05830123: https://clinicaltrials.gov/study/NCT05830123

## Connected records

- cancers: [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- drugs: [HS-20093](https://onco.cc/drugs/hs-20093/)

---
JSON: https://onco.cc/api/v1/entities/nct05830123.json